Circular RNA (Ribonucleic Acid) as well as mutant and related application thereof
By developing circular RNA hsa_circ_0069982 and its mutants, using its interaction with hnRNP M, the problem of difficulty in targeting and inhibiting hnRNP family proteins in the prior art is solved, and effective inhibition of tumor metastasis and chemotherapy resistance is achieved.
CN119662649AActive Publication Date: 2025-03-21SICHUAN UNIV
1 Cites 0 Cited by
Patent Information
- Application Number
- CN202411875933.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-19
- Publication Date
- 2025-03-21
- Estimated Expiration
- 2044-12-19
AI Technical Summary
Technical Problem
The prior art is difficult to effectively target and inhibit hnRNP family proteins, leading to tumor metastasis and chemotherapy resistance.
Method used
A circular RNA hsa_circ_0069982 and its mutant were developed to inhibit the function of hnRNP family proteins through direct interaction with hnRNP M, thereby inhibiting tumor metastasis and chemotherapy resistance.
Benefits of technology
hsa_circ_0069982 and its mutants significantly inhibit tumor metastasis and chemotherapy resistance, providing new targeted therapeutic approaches and means.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention discloses a circular RNA (Ribonucleic Acid) as well as a mutant and related application thereof, and relates to the field of medicines. The invention discloses the new application of hsacirc0069982 for the first time, hsacirc0069982 can be used as an aptamer RNA (Ribonucleic Acid) medicine for resisting hnRNP family proteins, and tumor metastasis can be remarkably inhibited and chemotherapy resistance of tumors can be reversed by increasing the expression quantity of hsacirc0069982; it is found that hsacirc0069982 can directly interact with hnRNP M, depending on a hsacirc0069982 key area, by optimizing and modifying the sequence of the area, an enhanced mutant can be obtained, the sequence is shown as SEQ ID NO: 2-6, and the enhanced mutant shows the hnRNP M binding capacity higher than that of a wild type. Through verification, the hsacirc0069982 and the enhanced mutant thereof can effectively inhibit tumor metastasis and chemotherapy drug resistance, and a new way and means are provided for tumor treatment.
Need to check novelty before this filing date? Find Prior Art